Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dianthus Therapeutics (DNTH) Capital Expenditures (2017 - 2025)

Dianthus Therapeutics has reported Capital Expenditures over the past 8 years, most recently at $5000.0 for Q3 2025.

  • Quarterly results put Capital Expenditures at $5000.0 for Q3 2025, down 80.0% from a year ago — trailing twelve months through Sep 2025 was $106000.0 (up 26.19% YoY), and the annual figure for FY2024 was $105000.0, down 4.55%.
  • Capital Expenditures for Q3 2025 was $5000.0 at Dianthus Therapeutics, down from $46000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for DNTH hit a ceiling of $129000.0 in Q2 2022 and a floor of -$46000.0 in Q3 2022.
  • Median Capital Expenditures over the past 4 years was $25000.0 (2024), compared with a mean of $28600.0.
  • Peak annual rise in Capital Expenditures hit 241.3% in 2023, while the deepest fall reached 83.72% in 2023.
  • Dianthus Therapeutics' Capital Expenditures stood at $29000.0 in 2022, then tumbled by 65.52% to $10000.0 in 2023, then surged by 210.0% to $31000.0 in 2024, then plummeted by 83.87% to $5000.0 in 2025.
  • The last three reported values for Capital Expenditures were $5000.0 (Q3 2025), $46000.0 (Q2 2025), and $24000.0 (Q1 2025) per Business Quant data.